Sustainable Cardiopulmonary Rehabilitation Services in the Home Act
Summary
The Sustainable Cardiopulmonary Rehabilitation Services in the Home Act (S.248) permanently codifies COVID-era telehealth flexibilities for Medicare-covered cardiac and pulmonary rehab in patient homes. This expands the addressable market for home health agencies and telehealth providers. Addus HomeCare ($ADUS) is the pure-play beneficiary; UnitedHealth ($UNH) gains through both its MA insurance and Optum home health arms. The bill is early-stage — referred to Senate Finance — requiring committee markup and passage before market impact materializes.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S.248 permanently codifies COVID-era telehealth flexibilities for Medicare cardiopulmonary rehab in the home — no new funding, but expands billable service categories for home health agencies.
- 2.$ADUS is the pure-play beneficiary with 100% home health exposure and near-term revenue potential of $15M–$40M annually.
- 3.$UNH benefits through both Medicare Advantage cost savings and Optum home health delivery, but effect is diluted across a $500B+ revenue base.
- 4.Bill is early-stage (referred to Senate Finance) — legislative risk is high; passage probability ~40–50% this Congress.
- 5.Market impact requires CMS rate-setting post-enactment, typically a 12–24 month lag before revenue realization.
Market Implications
Immediate market reaction is muted given early legislative stage. $ADUS provides direct exposure for investors betting on passage — the stock at $96.96 has not priced in the bill's potential, offering asymmetric upside if the bill advances. $UNH movement is dominated by broader earnings and regulatory news; this bill is a minor positive at the margin. Investors should monitor Senate Finance Committee schedule — a hearing or markup would be the first catalyst to move $ADUS. No short-term trading signal beyond current levels.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Permanent expansion of Medicare originating site designation to include the beneficiary's home for cardiac rehabilitation programs, intensive cardiac rehabilitation programs, and pulmonary rehabilitation programs, coupled with authorization for virtual presence of supervising physicians via audio-visual real-time communications technology.
Who must act
Medicare Administrative Contractors (MACs) and home health agencies furnishing cardiopulmonary rehabilitation under Medicare Part B.
What happens
Codifies COVID-era telehealth flexibilities permanently, removing the regulatory sunset risk that has constrained planning and investment in home-based rehab service lines. This expands the addressable market for home health agencies to include Medicare beneficiaries who previously had to travel to a hospital outpatient department for these services.
Stock impact
Addus HomeCare derives ~100% of revenue from home health and hospice services. This bill directly expands the service portfolio Addus can offer to its existing patient base and allows it to capture new patients who would otherwise not be candidates for home-based cardiopulmonary rehab. No capital expenditure required — pure regulatory expansion of billable services.
What the bill does
Permanent expansion of Medicare Part B-covered cardiopulmonary rehabilitation to the home via telehealth, codifying the originating site flexibility that allows patient homes to serve as the location of service delivery.
Who must act
Medicare fee-for-service beneficiaries and Medicare Advantage plans administered by UnitedHealthcare (UNH's insurance segment).
What happens
Medicare Advantage plans (UnitedHealthcare is the largest MA insurer with ~31% market share) can now design benefits around permanent home-based cardiopulmonary rehab, reducing facility costs and improving patient adherence. The Optum Health Services arm can also deploy its home health and telehealth infrastructure to deliver these services under MA contracts.
Stock impact
UnitedHealth Group benefits two ways: (1) UnitedHealthcare Medicare Advantage plans reduce medical cost ratios by substituting lower-cost home-based rehab for hospital outpatient visits; (2) Optum's home health division can expand billable service volume under both Medicare FFS and MA contracts. UNH's 30-day price surge (+41.62%) reflects broader sector momentum, but this bill provides a specific tailwind for its Medicare and Optum home health operations.
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Consolidated Appropriations Act, 2026
Protecting Health Care and Lowering Costs Act of 2025
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program.
American Innovation and R&D Competitiveness Act of 2025
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $526M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $782M Department of Veterans Affairs Contract
Medicare for All Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.